TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30851879

Group type: EXPERIMENTAL
Intervention: One anastomosis gastric bypass (OAGB)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: OAGB
Number of subjects: 253
Study: 28780364

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 26386824

Group type: EXPERIMENTAL
Intervention: Greater neighborhood physical order
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Greater neighborhood social order
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Greater perceived physical disorder
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Greater perceived social disorder
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Total neighborhood disorder
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Social disorder
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Social order
Number of subjects: 139
Study: 22836859

Group type: EXPERIMENTAL
Intervention: Low-fat diet (<20 g of fat/d) for 4 weeks in the suggestive group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-fat diet (<20 g of fat/d) for 4 weeks in the indeterminate group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (2 or less minor features of chronic pancreatitis)
Number of subjects: 45
Study: 21329887

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham (Group 5)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group 1 (PUUO without treatment)
Number of subjects: 40
Study: 19217992

Group type: COMPARATOR
Intervention: Below-knee cast
Number of subjects: 584

Group type: COMPARATOR
Intervention: Aircast brace
Number of subjects: 584

Group type: COMPARATOR
Intervention: Bledsoe boot
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Tubular compression bandage
Number of subjects: 584
Study: 17277040

Group type: EXPERIMENTAL
Intervention: Combined calcium and vitamin D supplementation (500 mg calcium citrate and 700 IU vitamin D(3) daily for 3 years)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 15104610

Group type: EXPERIMENTAL
Intervention: Radical hysterectomy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Simple hysterectomy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 41
Study: 11288011

Group type: EXPERIMENTAL
Intervention: Reviparin (low-molecular weight heparin) administered once daily subcutaneously for 7 to 10 days
Number of subjects: 262

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 262
Study: 10423639

Group type: EXPERIMENTAL
Intervention: 0.3 mg melatonin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7955250

Group type: EXPERIMENTAL
Intervention: Preservation of chordae tendineae and papillary muscles during mitral valve replacement (Pres group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No preservation of chordae tendineae and papillary muscles during mitral valve replacement (No Pres group)
Number of subjects: 16
Study: 3297467

Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine + oral captopril (50 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31985094

Group type: EXPERIMENTAL
Intervention: Kakato-tsurutsuru (Kt) socks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control socks
Number of subjects: 10
Study: 29317046

Group type: EXPERIMENTAL
Intervention: Modified technique with ice bag
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (standard technique)
Number of subjects: 21
Study: 26860796

Group type: EXPERIMENTAL
Intervention: JianYuTangKang (JYTK) plus metformin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Metformin plus placebo
Number of subjects: 112
Study: 23402523

Group type: EXPERIMENTAL
Intervention: Work and Social Adjustment Scale (WSAS)
Number of subjects: 73
Study: 23171519

Group type: EXPERIMENTAL
Intervention: +NL
Number of subjects: 23000

Group type: COMPARATOR
Intervention: ‐NL
Number of subjects: 23000

Group type: EXPERIMENTAL
Intervention: +SB
Number of subjects: 23000

Group type: COMPARATOR
Intervention: ‐SB
Number of subjects: 23000
Study: 20620119

Group type: EXPERIMENTAL
Intervention: Therapeutic Interactive Voice Response (TIVR) program for 4 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard follow-up care only (Control)
Number of subjects: 51
Study: 18467730

Group type: EXPERIMENTAL
Intervention: Current therapy
Number of subjects: 788
Study: 16898274

Group type: EXPERIMENTAL
Intervention: Faded knowledge of results (KR) frequency during observation of a model's performance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Knowledge of results (KR) on each trial
Number of subjects: 0
Study: 12910567

Group type: EXPERIMENTAL
Intervention: 150 international units of human IFN alfa administered oromucosally 3 times per day for 24 weeks
Number of subjects: 497

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Both groups (IFN alfa and placebo)
Number of subjects: 497
Study: 10781467

Group type: EXPERIMENTAL
Intervention: 10 mg spinal bupivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 7.5 mg spinal bupivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.75% hyperbaric bupivacaine
Number of subjects: 45
Study: 8620278

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 24
Study: 1485370

Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone (4.6-7.3 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oral oxycodone tablets (9.1 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oral oxycodone syrup (9.1 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rectal oxycodone suppository (30 mg)
Number of subjects: 48
Study: 2858149

Group type: EXPERIMENTAL
Intervention: Prolonged exposure in vivo
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Supportive therapy of dynamic type or simple basal therapy
Number of subjects: 115
Study: 30720931

Group type: EXPERIMENTAL
Intervention: Topical Daprodustat (1.0% at 100 mg/cm2 for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 0
Study: 30115263

Group type: EXPERIMENTAL
Intervention: Liberal clear fluid intake until premedication with midazolam
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard 2 h fluid fasting
Number of subjects: 162
Study: 26712714

Group type: EXPERIMENTAL
Intervention: High energy (100 mJ/pin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Moderate energy (60 mJ/pin)
Number of subjects: 30
Study: 24944057

Group type: EXPERIMENTAL
Intervention: Soy-HPWL diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meat-HPWL diet
Number of subjects: 20
Study: 22149337

Group type: EXPERIMENTAL
Intervention: Ecallantide, a potent and specific plasma kallikrein inhibitor, administered subcutaneously.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 19156709

Group type: EXPERIMENTAL
Intervention: Antidepressants augmented with atypical antipsychotics (AAP) for more than 2 weeks (n = 100)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Antidepressants only (non‐AAP group, n = 172)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: SSRIs with AAP (n unspecified)
Number of subjects: 272

Group type: COMPARATOR
Intervention: SSRIs without AAP (n unspecified)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: SSRIs and olanzapine (n unspecified)
Number of subjects: 272
Study: 17548728

Group type: EXPERIMENTAL
Intervention: Neopterin levels > or = 12.11 nmol/L at 7 days after ACS
Number of subjects: 3946

Group type: EXPERIMENTAL
Intervention: Neopterin levels > or = 12.11 nmol/L at 4 months after ACS
Number of subjects: 3946

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin among subjects with neopterin levels > or = 12.11 nmol/L at baseline
Number of subjects: 3946
Study: 14981383

Group type: EXPERIMENTAL
Intervention: Opinion leader strategy intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group hospitals
Number of subjects: 18
Study: 11246058

Group type: EXPERIMENTAL
Intervention: Aspirin (160 mg/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Warfarin (INR 2.8‐4.2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Combination of aspirin (75 mg/d) and warfarin (INR 2.0‐2.5)
Number of subjects: 42
Study: 9676516

Group type: EXPERIMENTAL
Intervention: Computer-assisted learning software 'Let's Play With...'
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard drill-and-practice methods
Number of subjects: 60
Study: 7978533

Group type: EXPERIMENTAL
Intervention: Combination of H1 and H2 histamine antagonists and a corticosteroid in gelatin capsules
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Active treatment (premedication)
Number of subjects: 22
Study: 2692344

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Diclofenac-Na 100 mg
Number of subjects: 36
Study: 29354937

Group type: EXPERIMENTAL
Intervention: Acupuncture technique (once a day for 15 days, 3 courses)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine basic rehabilitation therapy
Number of subjects: 56
Study: 27484021

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 4927

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 4927

Group type: EXPERIMENTAL
Intervention: Basal-bolus therapy
Number of subjects: 4927
Study: 25626750

Group type: EXPERIMENTAL
Intervention: Group 1 (self-explanation with examples and prompts)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Group 2 (self-explanation with examples without prompts)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (solved word puzzles)
Number of subjects: 54
Study: 23333095

Group type: EXPERIMENTAL
Intervention: High polyphenol olive oil (961 mg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Moderate polyphenol olive oil (289 mg/kg)
Number of subjects: 13
Study: 20687956

Group type: EXPERIMENTAL
Intervention: Behavioural interventions delivered in general practice including lifestyle counselling and motivational interviewing, diet education, and physical activity program consisting of two individual visits with a dietician or exercise physiologist and four group sessions.
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group receiving standard care without the additional behavioural interventions.
Number of subjects: 1200
Study: 18771406

Group type: EXPERIMENTAL
Intervention: PRO 140 0.5 mg/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PRO 140 2 mg/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PRO 140 5 mg/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 16157085

Group type: EXPERIMENTAL
Intervention: Ethically justified guidelines for pharmacologic research involving pregnant women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informed consent process shaped by pregnant patient's obligation to fetal patient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Referral of pregnant women to trials by physicians
Number of subjects: 0
Study: 15048595

Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no interferon)
Number of subjects: 19
Study: 9892407

Group type: EXPERIMENTAL
Intervention: Combined analysis of upper respiratory tract swab samples and cerebrospinal fluid (CSF) samples
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) samples alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Respiratory tract samples in control group
Number of subjects: 100
Study: 8688387

Group type: EXPERIMENTAL
Intervention: Low dose aspirin (60 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1864027

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Femoral vein clot
Number of subjects: 72
Study: 6357273

Group type: EXPERIMENTAL
Intervention: Topical acyclovir
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical steroids
Number of subjects: 40
Study: 30444150

Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT-tablet (5000, 10,000, or 20,000 JAU) for 14 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT-tablet (up-dosing regimen: 5,000 JAU on days 1-3, 10,000 JAU on days 4-7, 20,000 JAU on days 8-14) for 14 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29288190

Group type: COMPARATOR
Intervention: Standard TME surgery (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organ-saving treatment using long-course concurrent chemoradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organ-saving treatment using short-course radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active surveillance regime in case of complete clinical regression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local excision using transanal endoscopic microsurgery or other transanal techniques in case of incomplete clinical regression
Number of subjects: 0
Study: 26126563

Group type: EXPERIMENTAL
Intervention: Support from Aboriginal and Torres Strait Islander staff champions
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Research perceived to address a health priority for communities
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Onsite support from the research team
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Streamlined trial processes
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Major investments in time and resources
Number of subjects: 53
Study: 24707863

Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture (WAA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral morphine sulphate (MOR)
Number of subjects: 60
Study: 22978723

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RCA) in the region defined as ectopic focus by electrophysiology study (Group I)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-amplitude pacing in the region of 'perfect' mapping (Group II)
Number of subjects: 20
Study: 19173743

Group type: EXPERIMENTAL
Intervention: Neuro Emotional Technique (NET)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sham NET (placebo)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Existing medical regimen (Control)
Number of subjects: 93
Study: 15883209

Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated stents
Number of subjects: 92
Study: 12646763

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of 2 mg clonazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral (p.o.) administration of 2 mg clonazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of 2 mg clonazepam
Number of subjects: 12
Study: 10728943

Group type: EXPERIMENTAL
Intervention: Exercise conditioning (exercise group)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Low MESP group
Number of subjects: 641
Study: 8807096

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplantation (PBSCT) following high-dose chemoradiotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Debulking chemotherapy (vincristine, adriamycin, and dexamethasone or methylprednisolone)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-dose cyclophosphamide for stem cell mobilization
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PBSCT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low serum B2M before mobilization
Number of subjects: 40
Study: 1381611

Group type: EXPERIMENTAL
Intervention: arotinolol (10 mg bid)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 6208185

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 49

Group type: COMPARATOR
Intervention: Neither drug
Number of subjects: 49
Study: 31271885

Group type: EXPERIMENTAL
Intervention: Tacrolimus/Sirolimus (Tac/Sir)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Tacrolimus/Methotrexate (Tac/MTX)
Number of subjects: 304
Study: 27798510

Group type: EXPERIMENTAL
Intervention: Denosumab on top of standard treatment (calcium and vitamin D), n = 46
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard treatment alone, n = 44
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 90
Study: 25953802

Group type: EXPERIMENTAL
Intervention: Pegnivacogin followed by anivamersen
Number of subjects: 14

Group type: COMPARATOR
Intervention: Heparin/protamine
Number of subjects: 14
Study: 26330894

Group type: EXPERIMENTAL
Intervention: 3-hour repositioning schedule
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 4-hour repositioning schedule
Number of subjects: 123
Study: 21360104

Group type: EXPERIMENTAL
Intervention: Double crowns
Number of subjects: 25
Study: 19528902

Group type: EXPERIMENTAL
Intervention: Moderate exercise (60% VO(2) max)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intensive exercise (75% VO(2) max)
Number of subjects: 18
Study: 17505157

Group type: EXPERIMENTAL
Intervention: Methimazole (2.5‐7.5 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study: 15702855

Group type: EXPERIMENTAL
Intervention: Cornstarch thickened casein predominant formula
Number of subjects: 96

Group type: COMPARATOR
Intervention: Regular infant formula
Number of subjects: 96
Study: 12843887

Group type: EXPERIMENTAL
Intervention: Combined use of general and long‐acting local‐regional anesthesia with the 'bi‐clamp' procedure for bipolar electrosurgery
Number of subjects: 0
Study: 10916043

Group type: EXPERIMENTAL
Intervention: Dopamine agonists (bromocriptine, lisuride, cabergoline, ropinirole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low doses of L-dopa (added as a second step if necessary)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dopamine agonists
Number of subjects: 0
Study: 8885585

Group type: EXPERIMENTAL
Intervention: Bupropion 3 to 6 mg/kg per day, administered twice daily
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 1497527

Group type: EXPERIMENTAL
Intervention: In-the-bag fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Out-of-the-bag fixation
Number of subjects: 0
Study: 6389006

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure delivered by mask
Number of subjects: 38

Group type: COMPARATOR
Intervention: Incentive spirometry
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall incidence of pneumonia
Number of subjects: 38
Study: 30273448

Group type: EXPERIMENTAL
Intervention: Verum aiTBS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 28792260

Group type: EXPERIMENTAL
Intervention: P-ICE (panobinostat + ifosfamide + carboplatin + etoposide)
Number of subjects: 23
Study: 27485509

Group type: EXPERIMENTAL
Intervention: a-la-carte self-management program
Number of subjects: 50

Group type: COMPARATOR
Intervention: set menu control group
Number of subjects: 50

Group type: COMPARATOR
Intervention: usual care control group
Number of subjects: 50
Study: 24838894

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 22120301

Group type: EXPERIMENTAL
Intervention: Adjuvant autologous dendritic cell vaccine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional treatment only (Control group)
Number of subjects: 34
Study: 20649614

Group type: EXPERIMENTAL
Intervention: Goldmann Applanation Tonometry (GAT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dynamic Contour Tonometry (DCT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pseudoexfoliative Group (PG)
Number of subjects: 38
Study: 17562405

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite/tricalcium-phosphate-coated stems
Number of subjects: 84

Group type: COMPARATOR
Intervention: Noncoated stems
Number of subjects: 84
Study: 16201160

Group type: EXPERIMENTAL
Intervention: New technique (electrode placement 4 cm distal to ASIS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Old technique (electrode placement 1 cm medial to ASIS)
Number of subjects: 20
Study: 12197840

Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon‐α 2a/2b plus ribavirin
Number of subjects: 1728

Group type: COMPARATOR
Intervention: Interferon monotherapy
Number of subjects: 1728
Study: 9927366

Group type: EXPERIMENTAL
Intervention: 30-min spontaneous breathing trial
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: 120-min spontaneous breathing trial
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Reintubation
Number of subjects: 526
Study: 7569755

Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Ranitidine (300 mg)
Number of subjects: 266
Study: 2405090

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Captopril + Bendroflumethiazide
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Metoprolol + Bendroflumethiazide
Number of subjects: 104
Study: 6781156

Group type: EXPERIMENTAL
Intervention: Fixed combination of dihydralazin and propranolol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Antihypertensive standard therapy
Number of subjects: 36